

Curriculum Vitae

Naime Majidi Zolbanin

(Pharm.D., PhD of Pharmacology)

Address: Urmia university of medical sciences,

faculty of pharmacy,

department of pharmacology and toxicology

Tel: +98 44 32754992 (Ext.NO. 164)

Email: naimemajidi@yahoo.com, majidiz.n@umsu.ac.ir

Date of birth: March 12th, 1990

Nationality: Iranian

Education:

March 2014- October 2018:

PhD student of Pharmacology, Faculty of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran

Thesis title: "Effect of mucin 1 aptamer conjugated nanoparticles containing docetaxel and c-Met siRNA in metastatic breast cancer cells (SKBR3)", Supervisors: Prof.Alireza Mohajjel Nayebi and Prof Jafar Majidi Zolbanin

September 2008- February 2014:

PharmD, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

Thesis title: "Effect of testosterone on haloperidol induced catalepsy in male rats", Supervisor: Prof.Alireza Mohajjel Nayebi

September 2001- June 2008:

Farzanegan High school (National Organization for Development of Exceptional Talents), Tabriz, Iran

Work experience:

Curriculum Vitae

Naime Majidi Zolbanin

(Pharm.D., PhD of Pharmacology)

- Research Experience:

Cellular biology: Cell culture (SKBR3, CHO, MDA-MB468, hepatocytes), MTT assay, Flow-cytometry (Annexin V and PI), migration assay, cell imaging systems (Cytation 5), microscopy (light, inverted, fluorescence), liquid and solid culture of bacteria

Molecular biology: Primer designing, RNA extraction, reverse transcription, QRT-PCR, gene knock-downing by siRNA

Biochemistry: Western blotting, ELISA, gel electrophoresis

Pharmaceutical techniques: Titrations, spectrophotometry, chromatography (thin layer, ion exchange exclusion, HPLC), FTIR, Chitosan nanoparticles synthesis, aptamer conjugation to nanoparticles

Animal manipulation: Handling, blood sample collection methods from mice and rats (tail and intracardiac), IV/IP/IM/SC/gavage drug administration to animals, gonadectomy and ovariectomy, experimental animal models induction and assessment including: tumor induction, Parkinson's Disease, Cecal Ligation Puncture (CLP), depression and anxiety

- Teaching Experience:

2019-present: Pharmacology teaching to students of several majors, Urmia University of Medical Sciences

2016- 2018: Pharmacology teaching to students of Anesthesiology and Audiology, Tabriz University of Medical Sciences

2009-2011: English teaching in Goldis Language Institute of Tabriz

- Executive Experience:

2020-2023: Dean of Incubator center of health technology, Urmia University of Medical Sciences, Urmia, Iran

2020-present: Deputy of Research, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran

- Occupational Experience:

Curriculum Vitae

Naime Majidi Zolbanin

(Pharm.D., PhD of Pharmacology)

2019- present: Responsible pharmacist of Educational Pharmacies of Faculty of Pharmacy, Urmia, Iran

October 2014- October 2018: Responsible pharmacist of Pharmaceutical Information Center, Faculty of Pharmacy, Tabriz, Iran

June 2014-October 2014: Responsible pharmacist of Shahid Tofighi Pharmacy, Faculty of Pharmacy, Tabriz, Iran

- Administration Experience:

April (7-10), 2016: Executive member of "13th international congress of immunology and allergy", Tabriz, Iran

February (22-23), 2012: Executive member of "1st reasonable drug administration and use seminar", Tabriz, Iran

February (22-23), 2012: Executive member of " Interactions of combined parenteral drugs prescription and preparation" workshop, Tabriz, Iran

February (22-23), 2012: Executive member of " Classic and modern methods of prescription" workshop, Tabriz, Iran

April (13-14), 2011: Executive member of "Introduction to LANGENDORF method" national workshop, Tabriz, Iran

April (13-14), 2011: Executive member of "Cell culture" national workshop, Tabriz, Iran

April (13-14), 2011: Executive member of "Intracardiac and tail blood collection from rat" national workshop, Tabriz, Iran

April (13-14), 2011: Executive member of "Intraventricular injection" national workshop, Tabriz, Iran

April (13-14), 2011: Executive member of "Endnote" national workshop, Tabriz, Iran

Publications:

Curriculum Vitae

Naime Majidi Zolbanin

(Pharm.D., PhD of Pharmacology)

1. Hedayat M, Khezri MR, Jafari R, Malekinejad H, **Zolbanin NM**. Concomitant effects of paclitaxel and celecoxib on genes involved in apoptosis of triple-negative metastatic breast cancer cells. *Medical Oncology*. 2023 Aug; <https://doi.org/10.1007/s12032-023-02119-1>.
2. Hedayat M, Jafari R, **Zolbanin NM**. Selumetinib: a selective MEK1 inhibitor for solid tumor treatment. *Clinical and Experimental Medicine*. 2023 Jun;23(2):229-44.
3. Kiaie SH, **Zolbanin NM**, Ahmadi A, Bagherifar R, Valizadeh H, Kashanchi F, Jafari R. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. *Journal of Nanobiotechnology*. 2022 Dec;20(1):1-20.
4. Asemani Y, Najafi S, Ezzatifar F, **Zolbanin NM**, Jafari R. Recent highlights in the immunomodulatory aspects of Treg cell-derived extracellular vesicles: special emphasis on autoimmune diseases and transplantation. *Cell & Bioscience*. 2022 Dec;12(1):1-3.
5. Meidaninikjeh S, Sabouni N, Taheri M, Borjkhani M, Bengar S, **Zolbanin NM**, Khalili A, Jafari R. SARS-CoV-2 and Guillain–Barré Syndrome: Lessons from Viral Infections. *Viral Immunology*. 2022 Jul 1;35(6):404-17.
6. Khezri MR, Jafari R, Yousefi K, **Zolbanin NM**. The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions. *Experimental and Molecular Pathology*. 2022 May 27:104787.
7. Hedayat M, Jafari R, **Zolbanin NM**. Selumetinib: a selective MEK1 inhibitor for solid tumor treatment. *Clinical and Experimental Medicine*. 2022 Feb 16:1-6.
8. Khezri MR, Yousefi K, **Zolbanin NM**, Ghasemnejad-Berenji M. MicroRNAs in the pathophysiology of Alzheimer's disease and Parkinson's disease: an overview. *Molecular Neurobiology*. 2022 Jan 9:1-5.
9. Mardi A, Meidaninikjeh S, Nikfarjam S, **Zolbanin NM**, Jafari R. Interleukin-1 in COVID-19 infection: Immunopathogenesis and possible therapeutic perspective. *Viral Immunology*. 2021 Dec 1;34(10):679-88.
10. Aslan A, Aslan C, **Zolbanin NM**, Jafari R. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. *Pneumonia*. 2021 Dec;13(1):1-5.
11. Aslan C, Kiaie SH, **Zolbanin NM**, Lotfinejad P, Ramezani R, Kashanchi F, Jafari R. Exosomes for mRNA delivery: A novel biotherapeutic strategy with hurdles and hope. *BMC biotechnology*. 2021 Dec;21(1):1-2.
12. Rezaie J, Aslan C, Ahmadi M, **Zolbanin NM**, Kashanchi F, Jafari R. The versatile role of exosomes in human retroviral infections: from immunopathogenesis to clinical application. *Cell & Bioscience*. 2021 Dec;11(1):1-5.
13. Karpishev V, Mousavi SM, Sheykholeslami PN, Fathi M, Saray MM, Aghebati-Maleki L, Jafari R, **Zolbanin NM**, Jadidi-Niaragh F. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. *Life Sciences*. 2021 Nov 1;284:119132.
14. Khesht AM, Karpishev V, Gilan PS, Melnikova LA, Zekiy AO, Mohammadi M, Hojjat-Farsangi M, **Zolbanin NM**, Mahmoodpoor A, Hassannia H, Aghebati-Maleki L. Blockade of CD73 using

Curriculum Vitae

Naime Majidi Zolbanin

(Pharm.D., PhD of Pharmacology)

- siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo. *International journal of biological macromolecules*. 2021 Sep 1;186:849-63.
15. Khezri MR, **Zolbanin NM**, Ghasemnejad-Berenji M, Jafari R. Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection. *European journal of pharmacology*. 2021 Aug 15;905:174191.
 16. Asl SH, Nikfarjam S, **Zolbanin NM**, Nassiri R, Jafari R. Immunopharmacological perspective on zinc in SARS-CoV-2 infection. *International Immunopharmacology*. 2021 Jul 1;96:107630.
 17. Allahyari SE, Hajizadeh F, Zekiy AO, Mansouri N, Gilan PS, Mousavi SM, Masjedi A, Hassannia H, Ahmadi M, Mohammadi H, Yousefi M, **Zolbanin NM**, Jadidi-Niaragh F. Simultaneous inhibition of CD73 and IL-6 molecules by siRNA-loaded nanoparticles prevents the growth and spread of cancer. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2021 Jun 1;34:102384.
 18. Khezri MR, Malekinejad H, **Zolbanin NM**, Ghasemnejad-Berenji M. Anticancer potential of metformin: focusing on gastrointestinal cancers. *Cancer Chemotherapy and Pharmacology*. 2021 May;87(5):587-98.
 19. Nikfarjam S, Rezaie J, **Zolbanin NM**, Jafari R. Mesenchymal stem cell derived-exosomes: a modern approach in translational medicine. *Journal of Translational Medicine*. 2020 Dec;18(1):1-21.
 20. Jafari R, **Zolbanin NM**, Hosseini RF, Nassiri R. SARS-CoV-2 Novel Vaccine. *Archives of Healthcare*. 2020 Sep 21;1(3):Archives-of.
 21. Jafari R, **Zolbanin NM**, Nassiri R. The Urgent Priority of Global Health Research is to Prevent Transmission of Covid-19 through Vaccine Development.
 22. **Zolbanin NM**, Jafari R, Majidi J, Atyabi F, Yousefi M, Jadidi-Niaragh F, Zangbar MS, Asadi M, Nayebi AM. Apoptotic Effects of Mucin1 Aptamer-Conjugated Nanoparticles Containing Docetaxel and c-Met siRNA on SKBR3 Human Metastatic Breast Cancer Cells. *Jundishapur Journal of Natural Pharmaceutical Products*. 2019 Nov 30;14(4).
 23. Jafari R, **Zolbanin NM**, Majidi J, Atyabi F, Yousefi M, Jadidi-Niaragh F, Aghebati-Maleki L, Shanehbandi D, Zangbar MS, Rafatpanah H. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells. *Iranian biomedical journal*. 2019 Jan;23(1):21.
 24. **Zolbanin NM**, Jafari R, Majidi J, Atyabi F, Yousefi M, Jadidi-Niaragh F, Aghebati-Maleki L, Shanehbandi D, Zangbar MS, Nayebi AM. Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells. *Advanced pharmaceutical bulletin*. 2018 Aug;8(3):383.
 25. Shamsi M, Zolbanin JM, Mahmoudian B, **Zolbanin NM**, Maleki LA, Jafarabadi MA, Islamian JP. A study on drug delivery tracing with radiolabeled mesoporous

Curriculum Vitae

Naime Majidi Zolbanin

(Pharm.D., PhD of Pharmacology)

- hydroxyapatite nanoparticles conjugated with 2DG/DOX for breast tumor cells. Nuclear Medicine Review. 2018;21(1):32-6.
26. Jafari R, **Zolbanin NM**, Rafatpanah H, Majidi J, Kazemi T. Fc-fusion proteins in therapy: an updated view. Current medicinal chemistry. 2017 Apr 1;24(12):1228-37.
27. **Zolbanin NM**, Zolali E, Nayebi AM. Testosterone Replacement Attenuates Haloperidol-Induced Catalepsy in Male Rats. Advanced pharmaceutical bulletin. 2014;4(3):237.
28. Zolali E, Hamishehkar H, Maleki-Dizaji N, **Zolbanin NM**, Ghavimi H, Kouhsoltani M, et al. Selenium effect on oxidative stress factors in septic rats. Advanced pharmaceutical bulletin. 2014;4(3):289.
29. Doosti M-H, Bakhtiari A, Zare P, Amani M, **Zolbanin NM**, Babri S, et al. Impacts of early intervention with fluoxetine following early neonatal immune activation on depression-like behaviors and body weight in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2013;43:55-65.
30. Amani M, Samadi H, Doosti M-H, Azarfarin M, Bakhtiari A, **Zolbanin NM**, et al. Neonatal NMDA receptor blockade alters anxiety-and depression-related behaviors in a sex-dependent manner in mice. Neuropharmacology. 2013;73:87-97.

Books:

1. **Naime Majidi Zolbanin**, ... & Behzad Baradaran. Translation of " SiRNA delivery methods : methods and protocols" to persian. 2021, Etminan publication.
2. Haleh Vaez, Elmira Zolali, **Naime Majidi Zolbanin** and Dr Hossein Babaei. Questions of Pharmacology PhD Exams and Described Responses (1386-1393), 2015, Royan Pazhouh publication.

Congresses attended:

1. 24th International congress of Physiology and Pharmacology, 2019, Tehran, Iran
2. 15th Iranian Pharmaceutical Sciences, 2017, Hamedan, Iran
3. 13th international congress of immunology and allergy",2016, Tabriz, Iran
4. 21st International Iranian Congress of Physiology and Pharmacology, 2013, Tabriz, Iran
5. 13th Iranian Pharmaceutical Sciences Congress, 2012, Isfahan, Iran

Curriculum Vitae

Naime Majidi Zolbanin

(Pharm.D., PhD of Pharmacology)

6. 4th National Conference of E-Learning in Medical Science, 2011, Tabriz, Iran

Presentations:

1. Oral: **Naime Majidi Zolbanin**, Reza Jafari, Alireza Mohajjel Nayebi. Pharmacological effects of targeted treatment of human metastatic breast cancer cells (SKBR3) through Docetaxel and cMET siRNA. 24th International congress of Physiology and Pharmacology, 2019, Tehran, Iran
2. Poster: **Naime Majidi Zolbanin**, Reza Jafari, Fatemeh Atyabi, Jafar Majidi, Alireza Mohajjel Nayebi. Preparation, characterization and cell viability study of c-MET siRNA-loaded chitosan nanoparticles. 15th Iranian Pharmaceutical Sciences, 2017, Hamedan, Iran
3. Poster: **Naime Majidi Zolbanin**, Elmira Zolali and Alireza Mohajjel Nayebi. Effect of testosterone on haloperidol- induced catalepsy in male rats. 21st International Iranian Congress of Physiology and Pharmacology, 2013, Tabriz, Iran
4. Poster: Elmira Zolali, Hadi Hamishehkar, **Naime Majidi Zolbanin**, Hamed Ghavimi, Nasrin Maleki, Parina Asgharian. Is PAI an appropriate biomarker to estimate severity of sepsis in animal model?. 21st International Iranian Congress of Physiology and Pharmacology , 2013, Tabriz , Iran
5. Poster: **Naime Majidi Zolbanin**, Samad Shams Vahdati, Rouzbeh Rajaei Ghafouri, Ailar Toopal, Paria Habibollahi. Effectiveness of fluid resuscitation on survival of uncontrolled hemorrhagic shock (animal simulation). 13th Iranian Pharmaceutical Sciences Congress, 2012, Isfahan, Iran
6. Poster: Samad Shams Vahdati, Rouzbeh Rajaei Ghafouri, Paria Habibollahi, **Naime Majidi Zolbanin**, Giti Seyyed Ghiasi. The effect of 3% hypersaline, normalsaline and no fluid prescription on metabolic acidosis in uncontrolled hemorrhagic shock . 3rd EurAsian congress on emergency medicine, 2012, Antalya, Turkey.

Refereeing experience:

- 19th Iranian Pharmacy Students Seminar, 2015, Shiraz, Iran

Curriculum Vitae

Naime Majidi Zolbanin

(Pharm.D., PhD of Pharmacology)

- Journal of Pharmaceutical Sciences

Workshops attended:

1. " Teaching methods and skills", May 2017, Tabriz, Iran
2. " Introduction to PRISM", April 2017, Tabriz, Iran
3. " Introduction to SPSS and analyzing biomedical data", January 2017, Tabriz, Iran
4. " Principles of Real time PCR", May 2015, Tabriz, Iran
5. " Induction of spinal cord injury experimental model", October 2014, Tabriz, Iran
6. " Strok experimental models", November 2013, Tabriz, Iran
7. " Stem cell engineering", May 2011, Tabriz, Iran
8. "Introduction to LANGENDORF method", April 2011, Tabriz, Iran
9. "Cell culture", April 2011, Tabriz, Iran
10. "Intracardiac and tail blood collection from rat", April 2011, Tabriz, Iran
11. "Intraventricular injection", April 2011, Tabriz, Iran
12. " E-learning authoring tools", February 2011, Tabriz, Iran
13. " Poster designing and presentation methods", October 2010, Tabriz, Iran
14. " Introduction to EXCEL", April 2010, Tabriz, Iran
15. " REFERENCE MANAGER", April 2010, Tabriz, Iran

Memberships:

1. Iranian Society of Basic and Clinical Pharmacology, 2023-present
2. Iranian Society of Physiology and Pharmacology, 2013-present.
3. Student research committee, 2009-2011.

Awards:

Top educational process (Holding the 1st reasonable drug administration and use seminar), Shahid Motahari Educational Festival, April 2012, Tabriz, Iran

IT/Language Certificates:

Curriculum Vitae

Naime Majidi Zolbanin

(Pharm.D., PhD of Pharmacology)

- MSRT, 2014
- Goldis Certificate of English Language, 2010, Goldis Language Institute, Tabriz, Iran
- ICDL Core certificate, 2009